LetterLetter
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus
Lekh N. Dahal, Robert N. Barker and Frank J. Ward
The Journal of Rheumatology December 2019, jrheum.190678; DOI: https://doi.org/10.3899/jrheum.190678
Lekh N. Dahal
From the Centre for Drug Safety Science, Institute of Translational Medicine, University of Liverpool, Liverpool; Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. This work was supported by Arthritis Research UK (Grant no. 19282). F.J. Ward, L.N. Dahal, and R.N. Barker have filed a patent covering the use of the monoclonal antibody targeting the soluble isoform of CTLA-4 as a therapeutic agent. L.N. Dahal and F.J. Ward share joint senior authorship of this article. Address correspondence to F.J. Ward, University of Aberdeen, Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. E-mail: mmd475@abdn.ac.uk or L.N. Dahal, L.N.Dahal@liverpool.ac.uk
Robert N. Barker
From the Centre for Drug Safety Science, Institute of Translational Medicine, University of Liverpool, Liverpool; Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. This work was supported by Arthritis Research UK (Grant no. 19282). F.J. Ward, L.N. Dahal, and R.N. Barker have filed a patent covering the use of the monoclonal antibody targeting the soluble isoform of CTLA-4 as a therapeutic agent. L.N. Dahal and F.J. Ward share joint senior authorship of this article. Address correspondence to F.J. Ward, University of Aberdeen, Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. E-mail: mmd475@abdn.ac.uk or L.N. Dahal, L.N.Dahal@liverpool.ac.uk
Frank J. Ward
From the Centre for Drug Safety Science, Institute of Translational Medicine, University of Liverpool, Liverpool; Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. This work was supported by Arthritis Research UK (Grant no. 19282). F.J. Ward, L.N. Dahal, and R.N. Barker have filed a patent covering the use of the monoclonal antibody targeting the soluble isoform of CTLA-4 as a therapeutic agent. L.N. Dahal and F.J. Ward share joint senior authorship of this article. Address correspondence to F.J. Ward, University of Aberdeen, Immunity, Infection and Inflammation group, Division of Applied Medicine, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. E-mail: mmd475@abdn.ac.uk or L.N. Dahal, L.N.Dahal@liverpool.ac.uk
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus
Lekh N. Dahal, Robert N. Barker, Frank J. Ward
The Journal of Rheumatology Dec 2019, jrheum.190678; DOI: 10.3899/jrheum.190678